An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
Latest Information Update: 11 Oct 2022
At a glance
- Drugs DNV 3837 (Primary)
- Indications Clostridium difficile infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Deinove
- 06 Oct 2022 According to a Deinove media release, patient case data from the ongoing Phase II trial were presented at the ESCMID/ASM Conference in Dublin on October 5, 2022.
- 05 Oct 2022 Results published in the Media Release
- 05 Oct 2022 According to a Deinove media release, a case study excerpted from this study.